Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

BMRN

Biomarin Pharmaceutical Inc.

Dec 08 • 04:00PM ET

92.94

Dollar change -2.00
Percentage change -2.11	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	121.70	EPS (ttm)	0.76	Insider Own	1.95%	Shs Outstand	186.25M	Perf Week	0.56%
Market Cap	17.51B	Forward P/E	44.32	EPS next Y	2.10	Insider Trans	-1.17%	Shs Float	184.69M	Perf Month	8.69%
Income	147.02M	PEG	2.83	EPS next Q	0.24	Inst Own	96.57%	Short Float / Ratio	1.67% / 1.81	Perf Quarter	2.29%
Sales	2.29B	P/S	7.65	EPS this Y	29.72%	Inst Trans	2.15%	Short Interest	3.08M	Perf Half Y	1.72%
Book/sh	26.00	P/B	3.57	EPS next Y	115.52%	ROA	2.26%	Target Price	110.35	Perf Year	-10.37%
Cash/sh	5.98	P/C	15.55	EPS next 5Y	43.00%	ROE	3.11%	52W Range	76.02 - 117.77	Perf YTD	-10.19%
Dividend	-	P/FCF	498.78	EPS past 5Y	-	ROI	2.68%	52W High	-21.08%	Beta	0.36
Dividend %	-	Quick Ratio	1.65	Sales past 5Y	9.30%	Gross Margin	75.13%	52W Low	22.26%	ATR	2.21
Employees	3082	Current Ratio	2.54	Sales Q/Q	19.57%	Oper. Margin	4.93%	RSI (14)	62.47	Volatility	2.30% 2.15%
Optionable	Yes	Debt/Eq	0.22	EPS Q/Q	689.94%	Profit Margin	6.42%	Rel Volume	1.05	Prev Close	94.94
Shortable	Yes	LT Debt/Eq	0.12	Earnings	Nov 01 AMC	Payout	0.00%	Avg Volume	1.71M	Price	92.94
Recom	1.73	SMA20	4.62%	SMA50	7.80%	SMA200	2.54%	Volume	1,793,118	Change	-2.11%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-15-23	Initiated	Wells Fargo	Overweight	$100
Oct-23-23	Upgrade	Bernstein	Underperform → Mkt Perform	$82
Sep-28-23	Initiated	Raymond James	Mkt Perform
Sep-18-23	Initiated	UBS	Buy	$120
Jul-27-23	Initiated	Scotiabank	Sector Perform	$95
Jul-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$102
Jun-14-23	Resumed	Credit Suisse	Outperform	$120
Mar-21-23	Initiated	Bernstein	Underperform	$81
Feb-22-23	Downgrade	Oppenheimer	Outperform → Perform
Feb-21-23	Initiated	Citigroup	Neutral	$116
Jan-30-23	Initiated	BMO Capital Markets	Market Perform	$107
Jan-18-23	Initiated	Canaccord Genuity	Hold	$119
Oct-31-22	Upgrade	Oppenheimer	Perform → Outperform	$92 → $110
Jul-13-22	Initiated	Cantor Fitzgerald	Overweight	$110
Jun-13-22	Resumed	Wedbush	Neutral	$146 → $70
Apr-25-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$96 → $113
Nov-22-21	Upgrade	William Blair	Mkt Perform → Outperform
Oct-07-21	Resumed	Jefferies	Buy	$100
Sep-09-21	Upgrade	Stifel	Hold → Buy	$86 → $96
Jun-04-21	Resumed	Robert W. Baird	Outperform	$101

Show Previous Ratings

Dec-05-23 11:01AM	Billionaire Louis Bacons 10 Stock Picks with Huge Upside Potential (Insider Monkey)
Dec-02-23 05:06AM	4 Preeminent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip (Motley Fool)
Dec-01-23 11:31AM	Why Is BioMarin (BMRN) Up 14.3% Since Last Earnings Report? (Zacks)
Nov-29-23 09:13PM	Elfun Trusts Sheds Qualcomm in Q3, Embraces New Holdings (GuruFocus.com)
06:30AM	BioMarin secures hemophilia gene therapy coverage in Germany (BioPharma Dive)
11:09AM	Loading…
Nov-28-23 11:09AM	BioMarin prices hemophilia gene therapy at nearly 29,000 euros per vial in Germany (Reuters)
08:30AM	BioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Germany (PR Newswire)
Nov-16-23 08:47AM	3 Biotech Stocks Beating BioMarin Pharmaceutical (BMRN) (Entrepreneur: Stocks)
Nov-10-23 12:58AM	BioMarin gains on report Elliott has a stake: Insider trades & hedge funds weekly (Investing.com)
Nov-09-23 04:43PM	Under the Microscope: 3 Biotech Stocks Pioneering Tomorrows Cures (InvestorPlace)
03:49AM	Top 20 Drug Companies in the US by Revenue (Insider Monkey)
Nov-08-23 05:19AM	3 Promising Biotech Stocks Flying Under the Radar (InvestorPlace)
Nov-07-23 07:09PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research) +12.16%
05:07PM	BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion Stake (Investor's Business Daily)
02:24PM	BMRN Stock Jumps 12% as Activist Elliott Targets BioMarin Pharmaceuticals (InvestorPlace)
07:20PM	Loading…
Nov-06-23 07:20PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
Nov-04-23 05:06AM	4 Unique Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip (Motley Fool)
Nov-03-23 01:23AM	The Biomarin Pharmaceutical Inc (BMRN) Company: A Short SWOT Analysis (GuruFocus.com)
Nov-02-23 05:02PM	BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.17%
12:17PM	BioMarin (BMRN) Q3 Earnings in Line, Sales Miss, '23 View Cut (Zacks)
08:44AM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
07:15AM	BioMarin to replace CEO Bienaimé with Genentech veteran (BioPharma Dive)
Nov-01-23 06:30PM	BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:55PM	Biomarin Pharmaceutical Inc (BMRN) Reports 15% Total Revenue Growth in Q3 2023 (GuruFocus.com)
05:02PM	BioMarin: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year (PR Newswire)
04:02PM	BioMarin Announces Retirement of Jean-Jacques Bienaimé; Appoints Alexander Hardy President and Chief Executive Officer (PR Newswire)
04:02PM	BioMarin Announces Retirement of Jean-Jacques Bienaim; Appoints Alexander Hardy President and Chief Executive Officer (PR Newswire)
Oct-27-23 07:15AM	The Zacks Analyst Blog Highlights Bristol Myers, PTC Therapeutics, Beam Therapeutics and BioMarin Pharmaceutical (Zacks)
Oct-26-23 11:28AM	Biotech Stock Roundup: BMY's Q3 Results, PTCT Up on Deal, BEAM's Restructuring News (Zacks)
10:02AM	Loading…
10:02AM	Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-25-23 10:02AM	BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Oct-23-23 09:50AM	Pinterest upgraded, Salesforce downgraded: Wall Street's top analyst calls (The Fly)
Oct-20-23 04:20PM	UPDATE 2-BioMarin's dwarfism therapy gets FDA nod for expanded use (Reuters)
04:11PM	U.S. FDA approves expanded use of BioMarin's dwarfism therapy (Reuters)
04:05PM	U.S. Food and Drug Administration Approves BioMarin's VOXZOGO (vosoritide) for Children Under 5 Years with Achondroplasia (PR Newswire)
Oct-19-23 12:17PM	Elevance Health (ELV) Q3 Earnings Beat on Carelon Unit Strength (Zacks)
08:15AM	3 Under-the-Radar Biotech Stocks to Buy in 2023 (Motley Fool)
Oct-18-23 12:10PM	Why BioMarin (BMRN) Could Beat Earnings Estimates Again (Zacks)
Oct-17-23 08:30AM	BioMarin to Host Third-Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, November 1, at 4:30pm ET (PR Newswire)
Sep-23-23 05:06AM	4 Awe-Inspiring Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip (Motley Fool)
Sep-21-23 10:00AM	BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting (PR Newswire)
Sep-18-23 10:52AM	BioMarin's share prices fluctuate following Phase 3 clinical trial results (Investing.com)
09:55AM	Micron upgraded, PayPal downgraded: Wall Street's top analyst calls (The Fly)
Sep-15-23 12:50PM	Have Million-Dollar Gene Therapies Finally Reached An Inflection Point? (Investor's Business Daily)
09:29AM	BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO® (vosoritide) to Treat Children Aged 4 Months and Older with Achondroplasia (PR Newswire)
08:37AM	Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks (Investor's Business Daily)
Sep-11-23 08:30AM	BioMarin to Present Innovative Pipeline at R&D Day on September 12th in New York (PR Newswire)
Sep-06-23 08:30AM	BioMarin to Present Pipeline at Upcoming R&D Day on Tuesday, September 12th (PR Newswire)
Sep-05-23 08:30AM	BioMarin to Participate in Three Upcoming Investor Conferences (PR Newswire)
Sep-02-23 05:06AM	4 Preeminent Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip (Motley Fool)
Sep-01-23 11:31AM	Why Is Seattle Genetics (SGEN) Up 6.5% Since Last Earnings Report? (Zacks)
Aug-31-23 11:31AM	Why Is Incyte (INCY) Down 0.7% Since Last Earnings Report? (Zacks)
Aug-30-23 04:05PM	BioMarin Announces First Person Treated Commercially with ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Europe (PR Newswire)
Aug-12-23 05:06AM	4 Unforgettable Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip (Motley Fool)
Aug-01-23 01:37PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
12:35PM	BioMarin (BMRN) Q2 Earnings & Sales Top, Voxzogo Drives Sales (Zacks)
12:06PM	Q2 2023 Biomarin Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents)
Jul-31-23 07:30PM	BioMarin (BMRN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:35PM	BioMarin Pharmaceutical (BMRN) Tops Q2 Earnings and Revenue Estimates (Zacks)
04:29PM	BioMarin: Q2 Earnings Snapshot (AP Finance)
04:03PM	BioMarin Announces Strong Second Quarter 2023 Results and Record Breaking Revenues for the First Half of 2023, Including 13% Year Over Year Growth Year-to-date (PR Newswire)
Jul-27-23 09:56AM	Meta Platforms upgraded, Estee Lauder downgraded: Wall Street's top analyst call (The Fly)
Jul-16-23 07:58PM	Hunting for Growth: Goldman Sachs Says These 2 Stocks Could Rally up to 85% From Current Levels Heres Why They Have Solid Upside (TipRanks)
Jul-14-23 05:03PM	Disney has a lot of challenges, going to take a while to turn around: Strategist (Yahoo Finance Video)
Jul-13-23 11:46AM	BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong? (Simply Wall St.)
Jul-12-23 09:27AM	BioMarin to Host Second-Quarter 2023 Financial Results Conference Call and Webcast on Monday, July 31, at 4:30pm ET (PR Newswire)
Jul-10-23 03:52PM	Why Biotech Stocks Keep Falling on Good News (Barrons.com)
Jul-06-23 04:43PM	3 Biotech Stocks to Make Your Get Rich Dreams Come True (InvestorPlace)
10:36AM	Biotech Stock Roundup: BMRN's Gene Therapy Gets Approval, SGTX Up on Buyout by LLY (Zacks)
Jul-05-23 09:59AM	Netflix upgraded, Coinbase downgraded: Wall Street's top analyst calls (The Fly)
08:35AM	BioMarin Receives an Analyst's Love, but I'm Not in Love With Its Charts (TheStreet.com)
01:04AM	4 big analyst picks: Goldman Sachs warming to Netflix (Investing.com)
Jun-30-23 11:48AM	Amazon Hires Dozens of Former FTC Officials, Volkswagen Discusses With Tesla to Adopt North American Charging Standard, FDA Approves First Hemophilia A BioMarin Gene Therapy: Today's Top Stories (Benzinga)
10:57AM	BioMarin (BMRN) Gets FDA Nod for Hemophilia A Gene Therapy (Zacks)
Jun-29-23 07:45PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
05:31PM	New $2.9 Million Gene Therapy Promises to Remake Hemophilia Treatment (The Wall Street Journal)
05:12PM	New Gene Therapy Could Face Uphill Battle Despite FDA Approval (The Wall Street Journal)
04:05PM	$2.9 million gene therapy for severe hemophilia is approved by FDA (AP Finance)
02:42PM	UPDATE 3-US FDA approves BioMarin's gene therapy for hemophilia A (Reuters)
02:38PM	US FDA approves BioMarin's gene therapy for hemophilia A (Reuters)
02:34PM	U.S. Food and Drug Administration Approves BioMarin's ROCTAVIAN (valoctocogene roxaparvovec-rvox), the First and Only Gene Therapy for Adults with Severe Hemophilia A (PR Newswire)
Jun-27-23 01:48PM	10 Martin Shkreli Stock Picks and Their Performance (Insider Monkey)
Jun-22-23 09:30AM	3 Biotech Stocks to Buy With Explosive Upside Potential (InvestorPlace)
08:00AM	BioMarin to Present ROCTAVIAN (valoctocogene roxaparvovec) Data from Longest and Largest Hemophilia Gene Therapy Clinical Trial Program at the International Society on Thrombosis and Haemostasis (ISTH) 2023 Congress (PR Newswire)
Jun-16-23 10:31AM	The one-year returns for BioMarin Pharmaceutical's (NASDAQ:BMRN) shareholders have been favorable, yet its earnings growth was even better (Simply Wall St.)
Jun-07-23 08:55AM	3 Biotech Stocks That Could Skyrocket in the Next 12 Months (InvestorPlace)
May-26-23 11:31AM	Why Is BioMarin (BMRN) Down 4% Since Last Earnings Report? (Zacks)
May-25-23 04:03AM	14 Best Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
May-24-23 09:13PM	3 Biotech Stocks With Blockbuster Potential (InvestorPlace)
May-23-23 04:20AM	Heres Why You Should Invest in BioMarin Pharmaceutical (BMRN) (Insider Monkey)
May-18-23 12:59PM	PTC Therapeutics' (PTCT) PKU Drug Meets Study Goal, Up 7.6% (Zacks)
May-17-23 04:02PM	Why PTC Therapeutics Could Be Victorious In Its Rare-Disease Battle Against BioMarin Pharmaceuticals (Investor's Business Daily)
May-04-23 04:01PM	BioMarin to Participate in Bank of America 2023 Health Care Conference (PR Newswire)
May-03-23 01:07PM	BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-01-23 05:19AM	New Strong Sell Stocks for May 1st (Zacks)
Apr-27-23 11:01AM	BioMarin (BMRN) Q1 Earnings Top, Voxzogo Drives Sales (Zacks)
02:01AM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
Apr-26-23 08:00PM	BioMarin (BMRN) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
05:55PM	BioMarin Pharmaceutical (BMRN) Q1 Earnings and Revenues Surpass Estimates (Zacks)

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ajer Jeffrey Robert	EVP, Chief Commercial Officer	Aug 16	Sale	90.00	5,000	450,000	60,804	Aug 17 03:57 PM
FUCHS HENRY J	President, Worldwide R&D	Aug 10	Sale	90.43	12,000	1,085,111	176,187	Aug 11 01:59 PM
Guyer Charles Greg	EVP, Chief Technical Officer	Aug 09	Sale	93.30	5,360	500,109	40,041	Aug 10 04:47 PM
Davis George Eric	EVP, Chief Legal Officer	Aug 08	Sale	89.42	11,000	983,662	69,474	Aug 09 07:08 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Aug 08	Sale	88.29	6,000	529,740	422,732	Aug 09 07:05 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Aug 07	Sale	88.10	4,000	352,400	428,732	Aug 09 07:05 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	May 12	Option Exercise	67.81	46,500	3,153,165	472,713	May 16 05:22 PM
MEIER RICHARD A	Director	May 12	Option Exercise	67.81	8,500	576,385	117,494	May 17 06:14 PM
HERON ELAINE J	Director	May 12	Option Exercise	67.81	8,500	576,385	94,068	May 17 06:14 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	May 11	Option Exercise	67.81	30,000	2,034,300	456,213	May 15 04:58 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	May 11	Sale	94.67	30,000	2,840,226	426,213	May 15 04:58 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	May 10	Option Exercise	67.81	30,000	2,034,300	456,213	May 11 05:04 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	May 10	Sale	94.85	30,000	2,845,397	426,213	May 11 05:04 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	May 09	Option Exercise	67.81	30,000	2,034,300	456,213	May 11 05:04 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	May 09	Sale	94.93	30,000	2,847,973	426,213	May 11 05:04 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Apr 10	Option Exercise	67.81	10,000	678,100	435,896	Apr 12 04:08 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Apr 10	Sale	99.56	10,000	995,600	425,896	Apr 12 04:08 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Apr 06	Option Exercise	67.81	10,000	678,100	435,896	Apr 10 07:00 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Apr 06	Sale	96.13	10,000	961,300	425,896	Apr 10 07:00 PM
LAWLIS V BRYAN	Director	Apr 03	Option Exercise	67.81	8,500	576,385	37,450	Apr 04 07:59 PM
LAWLIS V BRYAN	Director	Apr 03	Sale	97.09	8,500	825,265	28,950	Apr 04 07:59 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Mar 13	Option Exercise	67.81	8,000	542,480	495,856	Mar 14 07:40 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Mar 13	Sale	90.45	8,000	723,600	487,856	Mar 14 07:40 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Mar 10	Option Exercise	67.81	15,000	1,017,150	502,856	Mar 14 07:40 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Mar 10	Sale	92.28	15,000	1,384,200	487,856	Mar 14 07:40 PM
Davis George Eric	EVP, Chief Legal Officer	Feb 24	Option Exercise	67.81	1,474	99,952	56,725	Feb 28 09:22 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Feb 13	Option Exercise	67.81	6,000	406,860	326,324	Feb 14 08:00 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Feb 13	Sale	109.15	6,000	654,900	320,324	Feb 14 08:00 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Feb 10	Option Exercise	67.81	15,000	1,017,150	335,324	Feb 14 08:00 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Feb 10	Sale	110.11	15,000	1,651,650	320,324	Feb 14 08:00 PM
Ajer Jeffrey Robert	EVP, Chief Commercial Officer	Jan 25	Option Exercise	67.81	49,000	3,322,690	90,088	Jan 27 09:35 PM
Ajer Jeffrey Robert	EVP, Chief Commercial Officer	Jan 25	Sale	115.70	49,000	5,669,134	41,088	Jan 27 09:35 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Jan 17	Option Exercise	67.81	10,000	678,100	330,424	Jan 18 09:41 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Jan 17	Sale	111.55	10,000	1,115,500	320,424	Jan 18 09:41 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Jan 13	Option Exercise	67.81	10,000	678,100	330,424	Jan 18 09:41 PM
Mueller Brian	EVP, Chief Financial Officer	Jan 13	Option Exercise	63.10	2,500	157,750	30,246	Jan 17 09:57 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Jan 13	Sale	112.25	10,000	1,122,500	320,424	Jan 18 09:41 PM
Mueller Brian	EVP, Chief Financial Officer	Jan 13	Sale	114.50	2,500	286,250	27,746	Jan 17 09:57 PM
Mueller Brian	EVP, Chief Financial Officer	Dec 13	Option Exercise	63.10	2,500	157,750	30,246	Dec 15 06:22 PM
Mueller Brian	EVP, Chief Financial Officer	Dec 13	Sale	107.50	2,500	268,750	27,746	Dec 15 06:22 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Dec 13	Sale	106.89	1,000	106,890	320,424	Dec 15 04:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BMRN

Biomarin Pharmaceutical Inc.

Upgrade your FINVIZ experience